Opinion
Video
A Case of a 66-Year-Old Man With Parkinson Disease and Dyskinesia
Panelists discuss how a 66-year-old man with 8 years of Parkinson disease presenting with severe peak-dose dyskinesia affecting basic functions like eating and speaking, plus 4 hours of daily “off” time despite frequent dosing, represents a patient who should not have been allowed to progress to such advanced motor complications, emphasizing that the preferred approach is early intervention to treat motor fluctuations and dyskinesia as they develop rather than waiting until patients reach this severely impaired state with complex symptoms requiring more intensive management strategies.
This segment explores advanced treatment options for the 54-year-old patient with Parkinson disease, particularly focusing on deep brain stimulation (DBS) as a viable consideration. Given her favorable clinical profile—9 years into disease progression, younger age, cognitive integrity, and absence of hallucinations, psychosis, or impulse control disorders—she represents an excellent candidate for DBS therapy. The discussion acknowledges recent innovations in adaptive programming for DBS systems, though the primary focus remains on pharmacological interventions. The patient's characteristics align perfectly with typical DBS candidacy criteria, making this an important treatment consideration alongside medication management.
Research analysis of delayed-release/extended-release amantadine phase 3 trials specifically examined patients meeting "5-2-1" DBS candidacy characteristics: 5 or more daily levodopa doses, at least 2 hours of “off” time, and at least 1 hour of troublesome dyskinesia. Results demonstrated robust efficacy with approximately 3 hours of increased good “on” time, approaching the benefits typically achieved with DBS. This data suggests that delayed-release/extended-release amantadine could serve as an intermediate step before proceeding to DBS, particularly valuable for young, cognitively intact patients who might benefit from delaying surgical intervention while maintaining significant symptom improvement.
The potential role of infusion pumps in this patient population remains an area of active research interest. Both fast carbidopa-levodopa and apomorphine infusions may offer benefits through pharmacokinetic optimization and a theoretical "deep priming" effect. Deep priming represents the opposite mechanism of dyskinesia —although pulsatile stimulation contributes to dyskinesia formation, continuous dopaminergic stimulation through infusions might reset hypersensitive receptors back to normal responsiveness. This continuous stimulation could potentially reduce both peak-trough medication levels and provide long-term receptor normalization, though these hypotheses require further clinical validation through dedicated research studies to establish definitive efficacy and optimal patient selection criteria.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
